FDA approves Tafinlar-Mekinist combination for BRAF-mutated anaplastic thyroid cancer - Healio

Channel NewsAsia

FDA approves Tafinlar-Mekinist combination for BRAF-mutated anaplastic thyroid cancer Healio The FDA extended approval of dabrafenib plus trametinib for the treatment of patients unresectable or metastatic anaplastic thyroid cancer with BRAF V600E mutations. This combination of dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis ... FDA Approves Combination for Rare Thyroid Cancer TypeCuretoday.com FDA approves Novartis combo therapy for aggressive type of thyroid cancerKFGO all 8 news articles »

from Health - Google News https://ift.tt/2KAzdHa